Navigation Links
Safety Concerns Prompt Prime to Remove Avandia(R) from Formulary
Date:12/6/2007

ST. PAUL, Minn., Dec. 6 /PRNewswire/ -- Pharmacy benefit manager Prime Therapeutics (Prime) recently announced the removal of the prescription drug Avandia(R) from its national formulary. After careful examination of clinical literature regarding the safety and efficacy of Avandia, Prime's National Pharmacy and Therapeutics (P&T) Committee has made the decision to remove the drug from its formulary. Prime's P&T Committee is a panel of pharmacists and physicians that meets quarterly and reviews drugs for Prime's formulary.

In May 2007, a meta-analysis by Nissen, et al, suggested that Avandia significantly increased the risk of heart attack. The results of this meta-analysis were also duplicated by the Food and Drug Administration (FDA) and Avandia manufacturer, GlaxoSmithKline. Consequently, in November 2007, the FDA announced that a black boxed warning for an increased risk for heart attacks in some patients would be added to Avandia's prescribing information.

Following the May publication of the Avandia meta-analysis, Prime's outcome clinicians began an in-depth analysis of Avandia utilization. An analysis of medical and pharmacy claims revealed that over 25 percent of patients on Avandia had a history of coronary artery disease or heart failure. The clinical evidence indicated that the use of Avandia in these patients may increase cardiovascular risk. Since the meta-analysis was released in May, Prime has seen a 58 percent decline in Avandia utilization.

"Prime has made this decision after a thorough analysis of the clinical literature examining the safety and efficacy of Avandia. Prime's National P&T Committee is committed to ensuring the safety and quality of Prime's formulary medications," stated Craig Mattson, Prime's Senior Director of Drug Technology Assessment and Formulary Development. "Prime takes drug safety warnings very seriously and our primary concern is the safety of our members."

Prime is committed to communicating to physicians the safety concerns surrounding Avandia and all other medications. Prime will continue to follow all market events surrounding drug safety and will make formulary changes when necessary.

Prime Therapeutics LLC is a pharmacy benefit management company dedicated to providing innovative, clinically based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to approximately 12.5 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minnesota, Prime Therapeutics is collectively owned by 10 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at http://www.primetherapeutics.com.


'/>"/>
SOURCE Prime Therapeutics LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. More proof needed of safety and quality of electronic personal health records
2. Back to School Means Backpack Safety
3. Seniors Need a Safety Plan in Face of Disasters
4. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
5. National Patient Safety Foundation Partners with Vocera Communications
6. PA Governors Occupational Safety and Health Conference Still Accepting Registrations
7. QI projects may -- or may not -- improve patient safety and outcomes
8. The National Center for Missing & Exploited Children, Wal-Mart, and Abbott Host Child Safety Events
9. Cutting Salt Wont Affect Foods Safety
10. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
11. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... provider of comprehensive treatment for eating disorders, is opening a brand new child ... provide individuals ages 8-17 and their families with even more specialized eating disorder ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian ... Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of the ... more than humbled by customer demand over the Mother’s Day Weekend promotion. So much ... that Bunion Bootie has completely replenished its inventory levels, it hopes to continue its ...
(Date:5/26/2016)... ... 26, 2016 , ... The introduction of our professional athletes coincides with the ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion ... Quick, wide receiver for Los Angeles who was a second round selection in the ...
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology: